CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics. The two companies will work together to ensure the production of Viking’s GLP ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, ...

This long-term agreement will help support the commercialization of VK2735.

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides large-scale ...

After earmarking a major chunk of change last year to bulk up in peptide production, European CDMO CordenPharma is putting ...